OSE Pharma (France) Performance
| OSE Stock | EUR 6.53 0.18 2.83% |
The company holds a Beta of 0.47, which implies possible diversification benefits within a given portfolio. As returns on the market increase, OSE Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding OSE Pharma is expected to be smaller as well. At this point, OSE Pharma SA has a negative expected return of -0.1%. Please make sure to check OSE Pharma's total risk alpha, kurtosis, price action indicator, as well as the relationship between the value at risk and rate of daily change , to decide if OSE Pharma SA performance from the past will be repeated at future time.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days OSE Pharma SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong technical and fundamental indicators, OSE Pharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 29.4 M | |
| Total Cashflows From Investing Activities | -827 K |
OSE |
OSE Pharma Relative Risk vs. Return Landscape
If you would invest 717.00 in OSE Pharma SA on December 18, 2024 and sell it today you would lose (64.00) from holding OSE Pharma SA or give up 8.93% of portfolio value over 90 days. OSE Pharma SA is producing return of less than zero assuming 3.3418% volatility of returns over the 90 days investment horizon. Simply put, 29% of all stocks have less volatile historical return distribution than OSE Pharma, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
OSE Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for OSE Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as OSE Pharma SA, and traders can use it to determine the average amount a OSE Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0299
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OSE |
Estimated Market Risk
| 3.34 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.1 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average OSE Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of OSE Pharma by adding OSE Pharma to a well-diversified portfolio.
OSE Pharma Fundamentals Growth
OSE Stock prices reflect investors' perceptions of the future prospects and financial health of OSE Pharma, and OSE Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on OSE Stock performance.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0528 | |||
| Profit Margin | (0.22) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 128.18 M | |||
| Shares Outstanding | 18.44 M | |||
| Price To Earning | 10.60 X | |||
| Price To Book | 2.64 X | |||
| Price To Sales | 3.69 X | |||
| Revenue | 26.31 M | |||
| EBITDA | (13.72 M) | |||
| Cash And Equivalents | 33.58 M | |||
| Cash Per Share | 0.84 X | |||
| Total Debt | 34.77 M | |||
| Debt To Equity | 7.20 % | |||
| Book Value Per Share | 2.53 X | |||
| Cash Flow From Operations | (9.92 M) | |||
| Earnings Per Share | (0.41) X | |||
| Total Asset | 101.88 M | |||
| Retained Earnings | 25 M | |||
| Current Asset | 30 M | |||
| Current Liabilities | 8 M | |||
About OSE Pharma Performance
By analyzing OSE Pharma's fundamental ratios, stakeholders can gain valuable insights into OSE Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if OSE Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if OSE Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
OSE Immunotherapeutics SA, a biotechnology company, focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. OSE Immunotherapeutics SA is headquartered in Nantes, France. OSE IMMUNO operates under Pharmaceuticals And Biosciences classification in France and is traded on Paris Stock Exchange. It employs 34 people.Things to note about OSE Pharma SA performance evaluation
Checking the ongoing alerts about OSE Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for OSE Pharma SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| OSE Pharma SA generated a negative expected return over the last 90 days | |
| OSE Pharma SA has high historical volatility and very poor performance | |
| The company reported the revenue of 26.31 M. Net Loss for the year was (16.85 M) with profit before overhead, payroll, taxes, and interest of 26.31 M. | |
| OSE Pharma SA has accumulated about 33.58 M in cash with (9.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.84. | |
| Roughly 39.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing OSE Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether OSE Pharma's stock is overvalued or undervalued compared to its peers.
- Examining OSE Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating OSE Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of OSE Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of OSE Pharma's stock. These opinions can provide insight into OSE Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for OSE Stock analysis
When running OSE Pharma's price analysis, check to measure OSE Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OSE Pharma is operating at the current time. Most of OSE Pharma's value examination focuses on studying past and present price action to predict the probability of OSE Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OSE Pharma's price. Additionally, you may evaluate how the addition of OSE Pharma to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |